摘要
目的探讨注射用丹参多酚酸盐联合重组人组织型纤溶酶原激酶衍生物静脉溶栓治疗进展性脑梗死的临床疗效。方法选取2017年3月至2019年3月本院收治的进展性脑梗死患者126例作为研究对象,随机分为对照组和联合组各63例。对照组采用重组人组织型纤溶酶原激酶衍生物静脉溶栓治疗,联合组在对照组基础上加用注射用丹参多酚酸盐治疗。比较两组总有效率、治疗前后血清同型半胱氨酸(Hcy)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)水平、治疗前及治疗后1个月神经功能、日常生活活动能力、不良反应发生率。结果联合组总有效率为95.24%,高于对照组的77.78%(P<0.05);治疗后联合组血清Hcy、TNF-α、hs-CRP水平均低于对照组(P<0.05);治疗后1个月联合组NIHSS评分低于对照组,Barthel指数高于对照组(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论注射用丹参多酚酸盐联合重组人组织型纤溶酶原激酶衍生物静脉溶栓治疗进展性脑梗死临床疗效显著,可有效减轻机体炎性反应,促进神经功能重建,改善患者日常生活活动能力,安全性高。
Objective To study the clinical effect of intravenous thrombolysis with salvia miltiorrhiza polyphenolate for injection combined with recombinant human tissue plasminogen kinase derivative in the treatment of progressive cerebral infarction.Methods A total of 126 patients with progressive cerebral infarction in our hospital from March 2017 to March 2019 were selected and randomly divided into control group and combined group,with 63 cases in each group.The control group was treated by intravenous thrombolysis with recombinant human tissue plasminogen kinase derivative,and the combined group was treated with salvianolate for injection on the basis of the control group.The total effective rate,serum levels of homocysteine(Hcy),tumor necrosis factor-alpha(TNF-alpha),hypersensitive C-reactive protein(hs-CRP),neurological function,activities of daily living and incidence of adverse reactions before and after treatment were compared between the two groups.Results The total effective rate of the combined group was95.24%,higher than 77.78%of the control group(P<0.05);the serum levels of Hcy,TNF-αand hs-CRP in the combined group were lower than those in the control group(P<0.05);the NIHSS score in the combined group was lower than that in the control group one month after treatment,and the Barthel index was higher than that in the control group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Salvia miltiorrhiza polyphenolate for injection combined with recombinant human tissue plasminogen kinase derivative intravenous thrombolytic therapy for progressive cerebral infarction has significant clinical efficacy,can effectively reduce the inflammatory response of the body,promote the reconstruction of nerve function,and improve the activity of daily life of patients with high safety.
作者
李太松
LI Tai-song(Department of Neurology,Yuzhou Hospital of Traditional Chinese Medicine,Xuchang,Henan 461670,China)
出处
《青岛医药卫生》
2020年第1期1-4,共4页
Qingdao Medical Journal
关键词
注射用丹参多酚酸盐
重组人组织型纤溶酶原激酶衍生物
进展性脑梗死
Salvianolate for injection
Recombinant human tissue plasminogen kinase derivative
Progressive cerebral infarction
